TLR Stimulation during T-cell Activation Lowers PD-1 Expression on CD8

Area of Science:

• Immunology
• Cancer Research
• Vaccinology

Background:

• T-cell checkpoint receptors, such as PD-1 and LAG-3, can inhibit antitumor immune responses.
• Blocking these receptors can enhance immunity, but checkpoint expression often coincides with T-cell activation.

Purpose of the Study:

• To investigate if T-cell checkpoint expression can be dissociated from T-cell activation using innate immune stimulation.
• To determine the role of toll-like receptor (TLR) agonists in modulating T-cell checkpoint expression.

Main Methods:

• Antigen-activated CD8+ T cells were treated with TLR agonists (TLR1/2, TLR7, TLR9).
• Expression of PD-1 on T cells was analyzed.
• Antitumor vaccines were combined with TLR1/2 or TLR7 ligands in tumor models.
• Antitumor immunity was assessed.

Main Results:

• TLR1/2, TLR7, and TLR9 ligands decreased PD-1 expression on antigen-activated CD8+ T cells.
• This effect was mediated by IL-12 from antigen-presenting cells.
• Combined vaccine and TLR ligand treatment induced antigen-specific CD8+ T cells with lower PD-1 expression and improved antitumor immunity.

Conclusions:

• Innate immune activation via TLR agonists can reduce PD-1 expression during CD8+ T-cell activation.
• TLR agonists can serve as vaccine adjuvants by modulating T-cell checkpoint expression.
• This approach enhances antitumor immunity.